Drugs / TAK-330
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05156983 | Aug 2022 → Aug 2028 expected | blood coagulation disease | Takeda | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156983 ↗ |
| Route | Intravenous | “25 IU/kg single intravenous infusion on Day 1” NCT05156983 ↗ |